Previously, when we suggested the use of LHRH peptide for the first time as a cancer-targeting moiety, we carried out an extensive set of experiments to prove that such cancer targeting significantly enhanced antitumor activity and limited the severe adverse side effects on healthy organs, tissues, and cells in vivo [55,57,58,59]. This evidence concerns the gene GNRH1 and cancer.